WXT timeline
Every WXT batch the index holds, newest manufacture date first, with the supplier's declared purity beside the median of the index's independent observations of the same lot.
| Lot | Compound | Manufactured | Quarter | Tests | Independent median | Spread (pp) | COA purity | Divergence (pp) | |
|---|---|---|---|---|---|---|---|---|---|
| WXT-2608-P3387 | Sermorelin | 10 Aug 2026 | 2026-Q3 | 1 | 98.97 | n<2 | 98.84 | -0.13 | |
| WXT-2605-B3833 | L-Glutathione (reduced) | 10 May 2026 | 2026-Q3 | 12 | 97.96 | 1.31 | 97.81 | -0.15 | |
| WXT-2604-K2596 | Leuprolide | 24 Apr 2026 | 2026-Q3 | 12 | 98.83 | 0.93 | 98.88 | +0.05 | |
| WXT-2604-C3248 | Semaglutide | 05 Apr 2026 | 2026-Q3 | 12 | 97.18 | 1.11 | 97.00 | -0.18 | |
| WXT-2603-K2168 | BPC-157 | 14 Mar 2026 | 2026-Q2 | 2 | 97.62 | 0.83 | 97.51 | -0.11 | |
| WXT-2602-G2962 | Semaglutide | 27 Feb 2026 | 2026-Q2 | 3 | 97.44 | 0.42 | 97.47 | +0.03 | |
| WXT-2602-W3200 | BPC-157 | 16 Feb 2026 | 2026-Q2 | 7 | 97.84 | 1.19 | 97.76 | -0.08 | |
| WXT-2602-F2275 | CJC-1295 with DAC | 03 Feb 2026 | 2026-Q2 | 1 | 98.02 | n<2 | 98.57 | +0.55 | |
| WXT-2601-P3156 | CJC-1295 (no DAC) | 22 Jan 2026 | 2026-Q1 | 8 | 98.69 | 0.87 | 98.96 | +0.27 | |
| WXT-2601-A2974 | Tesamorelin | 07 Jan 2026 | 2026-Q1 | 1 | 97.17 | n<2 | 97.05 | -0.12 | |
| WXT-2512-F3324 | Semaglutide | 28 Dec 2025 | 2026-Q2 | 5 | 98.85 | 1.49 | 99.74 | +0.89 | |
| WXT-2512-K3109 | MOTS-c | 16 Dec 2025 | 2026-Q1 | 5 | 97.72 | 1.15 | 97.69 | -0.03 | |
| WXT-2512-P2820 | L-Glutathione (reduced) | 03 Dec 2025 | 2026-Q2 | 12 | 98.10 | 1.01 | 98.24 | +0.14 | |
| WXT-2511-N3100 | CJC-1295 (no DAC) | 21 Nov 2025 | 2026-Q1 | 4 | 98.01 | 1.21 | 98.50 | +0.49 | |
| WXT-2511-P3368 | MOTS-c | 17 Nov 2025 | 2026-Q2 | 8 | 98.65 | 1.57 | 98.91 | +0.26 | |
| WXT-2511-P3680 | Melanotan II | 13 Nov 2025 | 2026-Q1 | 1 | 98.99 | n<2 | 99.11 | +0.12 | |
| WXT-2509-A3902 | Semaglutide | 24 Sep 2025 | 2025-Q4 | 9 | 98.08 | 1.20 | 98.34 | +0.26 | |
| WXT-2508-G2836 | Semaglutide | 25 Aug 2025 | 2025-Q3 | 5 | 98.45 | 1.10 | 98.81 | +0.36 | |
| WXT-2508-G2536 | IGF-1 LR3 | 10 Aug 2025 | 2025-Q3 | 6 | 96.97 | 0.86 | 96.96 | -0.01 | |
| WXT-2507-R4042 | PT-141 (Bremelanotide) | 23 Jul 2025 | 2025-Q3 | 12 | 99.04 | 1.10 | 99.05 | +0.01 | |
| WXT-2507-N3348 | Semaglutide | 18 Jul 2025 | 2025-Q4 | 3 | 97.24 | 0.35 | 97.41 | +0.17 | |
| WXT-2507-J4054 | TB-500 | 18 Jul 2025 | 2025-Q4 | 5 | 97.85 | 0.39 | 97.96 | +0.11 | |
| WXT-2506-D3300 | Sermorelin | 28 Jun 2025 | 2025-Q3 | 2 | 98.99 | 0.17 | 98.98 | -0.01 | |
| WXT-2506-V2798 | Enclomiphene citrate | 06 Jun 2025 | 2025-Q3 | 5 | 99.08 | 0.43 | 98.82 | -0.26 | |
| WXT-2506-M1881 | BPC-157 | 03 Jun 2025 | 2025-Q3 | 10 | 99.13 | 1.08 | 99.28 | +0.15 | |
| WXT-2505-T3334 | Tirzepatide | 30 May 2025 | 2025-Q3 | 5 | 97.98 | 0.74 | 98.26 | +0.28 | |
| WXT-2505-J2528 | N-Acetyl Semax Amide | 29 May 2025 | 2025-Q4 | 7 | 98.40 | 0.65 | 98.65 | +0.25 | |
| WXT-2505-E2684 | Semaglutide | 25 May 2025 | 2025-Q4 | 10 | 97.75 | 1.04 | 97.63 | -0.12 | |
| WXT-2505-P3150 | Semaglutide | 16 May 2025 | 2025-Q4 | 6 | 99.45 | 0.82 | 99.60 | +0.15 | |
| WXT-2505-B3939 | Tesamorelin | 09 May 2025 | 2025-Q3 | 1 | 96.86 | n<2 | 96.50 | -0.36 | |
| WXT-2505-M2430 | 5-Amino-1MQ | 04 May 2025 | 2025-Q2 | 9 | 98.71 | 1.36 | 99.09 | +0.38 | |
| WXT-2504-L3444 | Liraglutide | 28 Apr 2025 | 2025-Q3 | 1 | 97.45 | n<2 | 97.09 | -0.36 | |
| WXT-2502-N3730 | ARA-290 | 21 Feb 2025 | 2025-Q2 | 4 | 99.23 | 1.19 | 99.50 | +0.27 | |
| WXT-2502-U4093 | PT-141 (Bremelanotide) | 16 Feb 2025 | 2025-Q2 | 1 | 98.40 | n<2 | 98.50 | +0.10 | |
| WXT-2502-F2050 | MK-677 (Ibutamoren mesylate) | 16 Feb 2025 | 2025-Q1 | 8 | 99.61 | 0.52 | 99.82 | +0.21 | |
| WXT-2501-X2463 | Survodutide | 16 Jan 2025 | 2025-Q2 | 10 | 97.87 | 0.85 | 97.64 | -0.23 | |
| WXT-2501-J3079 | BPC-157 | 05 Jan 2025 | 2025-Q1 | 9 | 98.73 | 0.48 | 98.68 | -0.05 | |
| WXT-2411-G2069 | GHRP-6 | 28 Nov 2024 | 2024-Q4 | 5 | 99.04 | 0.89 | 99.39 | +0.35 | |
| WXT-2411-H2426 | Sermorelin | 25 Nov 2024 | 2025-Q1 | 1 | 97.89 | n<2 | 98.00 | +0.11 | |
| WXT-2411-F3188 | Tirzepatide | 16 Nov 2024 | 2025-Q2 | 12 | 98.59 | 1.57 | 98.22 | -0.37 | |
| WXT-2411-R3766 | PT-141 (Bremelanotide) | 01 Nov 2024 | 2025-Q1 | 8 | 98.49 | 0.36 | 98.02 | -0.47 | |
| WXT-2410-J3109 | Ipamorelin | 30 Oct 2024 | 2024-Q4 | 1 | 99.06 | n<2 | 99.67 | +0.61 | |
| WXT-2410-M2421 | PT-141 (Bremelanotide) | 26 Oct 2024 | 2025-Q1 | 6 | 98.36 | 1.24 | 98.30 | -0.06 | |
| WXT-2410-J3009 | BPC-157 | 06 Oct 2024 | 2024-Q4 | 4 | 98.41 | 0.65 | 98.58 | +0.17 | |
| WXT-2409-Y3760 | CJC-1295 with DAC | 21 Sep 2024 | 2025-Q1 | 7 | 97.20 | 0.99 | 98.94 | +1.74 | |
| WXT-2408-P3767 | MK-677 (Ibutamoren mesylate) | 02 Aug 2024 | 2024-Q4 | 9 | 99.10 | 0.65 | 99.00 | -0.10 | |
| WXT-2406-W3910 | Selank | 28 Jun 2024 | 2024-Q3 | 2 | 99.58 | 0.42 | 99.88 | +0.30 | |
| WXT-2404-N2537 | GHRP-2 | 19 Apr 2024 | 2024-Q3 | 11 | 98.57 | 1.68 | 98.37 | -0.20 | |
| WXT-2402-B2476 | Tirzepatide | 16 Feb 2024 | 2024-Q3 | 7 | 99.14 | 1.34 | 98.93 | -0.21 | |
| WXT-2402-W2466 | Semax | 06 Feb 2024 | 2024-Q2 | 4 | 98.69 | 0.36 | 98.89 | +0.20 | |
| WXT-2312-M2386 | BPC-157 | 05 Dec 2023 | 2024-Q1 | 2 | 97.81 | 0.09 | 97.72 | -0.09 |